Stockwinners Market Radar for April 09, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:10 EDT Condor Hospitality Trust says annual report contains 'going concern' paragraph - Hospitality Trust, pursuant to the disclosure requirements of the NYSE American Company Guidelines Sections 401(h) and 610(b), the company advises that its audited financial statements for the fiscal year ended December 31, 2020, included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 as filed with the SEC, contains an audit opinion from its independent registered public accounting firm that due to circumstances related to a loan includes an explanatory paragraph related to the company's ability to continue as a going concern. Matters relating to this item are set forth in the Form 10-K, where the company expresses its views with respect to third party actions related to a specific loan, the underlying reason for the going concern paragraph. This advisement does not represent any change or amendment to the company's financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

17:40 EDT Electronic Arts CFO sells 5,975 shares of common stock - In a regulatory filing, Electronic Arts disclosed that its CFO Gerald Volas sold 5,975 shares of common stock on April 7th in a total transaction size of $848K, reducing his stake by about 17%.

17:01 EDT Cameco restarting Cigar Lake mine in April - Cameco announced that it plans to restart production in April at its Cigar Lake uranium mine located in northern Saskatchewan. Production at Cigar Lake was temporarily suspended in December 2020 due to increasing risks posed by the Coronavirus (COVID-19) pandemic. At that time, the availability of workers in critical areas was shrinking due to the pandemic, with more individuals screening out or residing in communities with pandemic-related travel restrictions. "The safety of our workers, their families and communities is always our top priority," said Cameco president and CEO Tim Gitzel. "In recent months we have implemented several enhanced safety protocols for Cigar Lake, including increased distancing between passengers on flights, mandatory medical-grade masks for all workers and increased sanitization and physical barriers in our eating areas. We also worked with the Saskatchewan Health Authority and have established a licensed COVID-19 testing facility at the mine site. These further safety measures, along with the provincial vaccine rollout program and increased confidence around our ability to manage our critical workforce, have given us greater certainty that Cigar Lake will be able to operate safely and sustainably." As the restart process begins, Cameco will closely monitor the COVID-19 case counts and the ongoing success of the vaccine rollout, and will continue to have regular dialogue with public health authorities and northern Saskatchewan leaders.

16:54 EDT Raymond James exec Allaire sells over 9,000 common shares - In a regulatory filing, Raymond James executive VP of RJA Bella Loykhter Allaire disclosed the sale of 9,330 common shares of the company on March 29 at a price of $123.59 per share.

16:32 EDT TD Holdings receives noncompliance notification from Nasdaq - TD Holdings announced that it has received a notice from Nasdaq notifying the company that, because its Form 10-K for the FY20 was not filed with the Securities and Exchange Commission by the required due date of March 31, the company is therefore not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250. This notice received has no immediate effect on the listing or trading of the company's shares. The company expects and intends to submit to Nasdaq the compliance plan by June 4.

16:12 EDT Interactive Brokers chairman sells 40K shares of common stock - In a regulatory filing, Interactive Brokers disclosed that its Chairman Thomas Peterffy sold 40K shares of common stock on April 7th in a total transaction size of $2.94M.

16:01 EDT Seagen, Genmab say FDA accepts BLA for tisotumab vedotin for priority review - Seagen (SGEN) and Genmab (GMAB) announced that the U.S. Food and Drug Administration has accepted for Priority Review the Biologics License Application seeking accelerated approval for tisotumab vedotin. This BLA requests FDA approval of tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Under the Prescription Drug User Fee Act, the FDA has set a target action date of October 10, 2021. Tisotumab vedotin is an investigational antibody-drug conjugate directed to tissue factor, a cell-surface protein expressed on multiple solid tumors including cervical cancer, and is associated with tumor growth, angiogenesis, metastasis and poor prognosis. "The FDA's filing of the tisotumab vedotin BLA with Priority Review marks an important step forward for this ADC as a potential treatment for patients with recurrent or metastatic cervical cancer," said Roger Dansey, M.D., Chief Medical Officer at Seagen. "We are collaborating closely with the FDA throughout the review process to make this important therapy available to patients."

15:20 EDT Tesla CEO offers 'congrats to NIO' on 100,000 vehicle milestone - After CleanTechnica posted a link to a story it wrote regarding Chinese electric carmaker NIO (NIO) having produced its 100,000th vehicle, Tesla (TSLA) CEO Elon Musk tweeted in reply: "Congrats to NIO. That is a tough milestone." Reference Link

14:25 EDT Ancora says ISS 'endorsed Ancora's case for boardroom change' at Blucora - Ancora Holdings, which collectively with the other participants in its solicitation beneficially owns approximately 3.4% of the outstanding common stock of Blucora, said that Institutional Shareholder Services "has endorsed Ancora's case for boardroom change," recommended for the election of Fredrick DiSanto, and "only recommends re-electing six current, unopposed members "of the board of directors of Blucora. In addition, Glass, Lewis & Co. "has released a report that acknowledges Ancora raises legitimate concerns," according to the investment firm. Ancora is seeking to elect DiSanto, Cindy Schulze Flynn, Robert MacKinlay and Kimberly Smith Spacek to Blucora's ten-member board at the company's annual meeting of stockholders on April 21.

13:07 EDT Baker Hughes reports U.S. rig count up 2 to 432 rigs - Baker Hughes reports that the U.S. rig count is up 2 from last week at 432 with oil rigs unchanged at 337, gas rigs up 2 to 93, and miscellaneous rigs unchanged at 2. The U.S. Rig Count is down 170 rigs from last year's count of 602, with oil rigs down 167, gas rigs down 3 and miscellaneous rigs unchanged at 2. The U.S. Offshore Rig Count is down 3 to 11, down 7 year-over-year. The Canada Rig Count is down 11 from last week to 58, with oil rigs down 5 to 19, gas rigs down 6 to 39. The Canada Rig Count is up 23 rigs from last year's count of 35, with oil rigs up 13, gas rigs up 10.

12:57 EDT Pfizer, BioNTech seek expansion of vaccine EUA to include 12-15 year olds - Pfizer (PFE) and BioNTech (BNTX) requested amendments to the U.S. Emergency Use Authorization of the Pfizer-BioNTech vaccine to expand the use in adolescents 12 to 15 years of age. The companies plan to request similar rulings by other regulatory authorities worldwide in coming days. "These requests are based on data from the pivotal Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, which demonstrated 100 percent efficacy and robust antibody response after vaccination with the COVID-19 Vaccine," they said in a statement. Reference Link

12:04 EDT Facebook removes 16,000 groups trading fake reviews, says U.K.'s CMA - The U.K.'s Competition and Markets Authority said that Facebook has taken down 16,000 trading groups with suspensions or bans for users who create groups and profiles that buy and sell fake product reviews. This latest action by the Competition and Markets Authority (CMA) follows reports that fake and misleading reviews continued to be bought and sold on the social media platforms. In January 2020, Facebook committed to better identify, investigate and remove groups and other pages where fake and misleading reviews were being traded, and prevent them from reappearing. Facebook gave a similar pledge in relation to its Instagram.com business in May 2020, after the CMA had identified similar concerns. A follow-up investigation found evidence that the illegal trade in fake reviews was still taking place on both Facebook and Instagram and the CMA intervened for a second time. Facebook has now removed a further 16,000 groups that were dealing in fake and misleading reviews. It has also made further changes to its systems for identifying, removing and preventing such content on its social media platforms to ensure it is fulfilling its previous commitments. Reference Link

12:00 EDT Coursera falls -7.5% - Coursera is down -7.5%, or -$4.18 to $51.82.

12:00 EDT Natuzzi rises 10.3% - Natuzzi is up 10.3%, or $1.46 to $15.66.

12:00 EDT FuboTV rises 17.5% - FuboTV is up 17.5%, or $3.62 to $24.32.

10:56 EDT AT&T to record Q1 non-cash pre-tax actuarial gain of $2.8B on pension obligation - In a regulatory filing earlier, AT&T stated: "For the quarter ended March 31, 2021, due in part to our recent resizing and restructuring of operations, we anticipate total distributions from the pension plan will exceed the threshold of service and interest costs for 2021, requiring us to follow settlement accounting and remeasure our pension benefit obligation at each quarter-end in 2021. For the quarter ended March 31, 2021, we expect to record a non-cash pre-tax actuarial gain of approximately $2.8B, which is primarily due to an increase in the discount rate used to measure the obligation. We recognize actuarial gains and losses on pension and postretirement plan assets and obligations in our consolidated results as a component of other income/expense. This gain will be included in our reported results but excluded in adjusted earnings, consistent with our historical practice for actuarial gains and losses."

10:00 EDT Ouster falls -6.8% - Ouster is down -6.8%, or -67c to $9.17.

10:00 EDT JinkoSolar falls -8.5% - JinkoSolar is down -8.5%, or -$3.31 to $35.55.

10:00 EDT Turquoise Hill rises 6.0% - Turquoise Hill is up 6.0%, or $1.08 to $19.07.

09:55 EDT Sorrento's Scilex gets approval from FDA for Ztlido - Sorrento Therapeutics' majority owned subsidiary Scilex was informed in a letter from the FDA of an NDA approval for Ztildo for relief of pain associated with post-herpetic neuralgia, according to a post to the agency's website. Reference Link

09:47 EDT Global Ship Lease falls -7.2% - Global Ship Lease is down -7.2%, or -$1.01 to $13.05.

09:47 EDT FuboTV rises 7.6% - FuboTV is up 7.6%, or $1.57 to $22.27.

09:47 EDT Audacy rises 8.9% - Audacy is up 8.9%, or 45c to $5.48.

09:43 EDT UTime Limited trading resumes

09:34 EDT Franklin Wireless Corporation trading halted, volatility trading pause

09:16 EDT Zynex announces new corporate headquarters - Zynex announced that it is moving to a new corporate headquarters to accommodate its' continued growth. The new headquarters is located at 9655 Maroon Circle, Englewood CO 80112. The new building is down the street from the existing headquarters and will expand the footprint from approximately 86,000 square feet to 110,754 square feet with a first right of refusal to occupy an additional 56,158 square feet in the building. An 8-K has been filed with the details of the lease arrangements. The lease is for eighty-four months and terminates on April 29, 2028.

09:06 EDT Castor Maritime announces vessel acquisition - Castor Maritime announced that it entered, through a separate wholly-owned subsidiary, into an agreement to purchase a 2011 Japanese-built Panamax dry bulk carrier from an unaffiliated third-party for a purchase price of $18.48M. The acquisition is expected to be consummated by taking delivery of the vessel within Q2 and is subject to the satisfaction of certain customary closing conditions. Petros Panagiotidis, CEO of Castor, commented, "We are pleased to announce our ninth vessel acquisition in 2021 with the addition of another Panamax dry bulk vessel to Castor's fleet. Our focus remains on deploying our capital and growing our fleet through timely acquisitions of vessels across shipping segments."

09:03 EDT Franklin Wireless responds to Verizon Jetpack recall - Franklin Wireless (FKWL) has been notified that Verizon Wireless (VZ) has issued a voluntary recall of its Jetpack Hotspot devices imported by Franklin. Franklin is continuing to work with its battery and device manufacturing partners to determine the cause and extent of the concerns. At this time, fewer than 20 reports of trouble have been received with over 2 million devices in sold over the last three and a half years.

08:56 EDT AutoNation partners with Inter Miami CF - AutoNation announced that it has partnered with Inter Miami CF, an American professional soccer club based in South Florida. AutoNation will be the official and exclusive automotive partner of Inter Miami, which includes naming rights of the stadium and branding on training kits. This partnership amplifies AutoNation and Inter Miami's commitment to driving out cancer by leveraging the power of soccer and its strong fan base. In addition, the partnership includes extensive TV and digital exposure, with the entitlement of the Inter Miami Digital Live Stream via their Inter Miami App and the Inter Miami Spanish language streaming show. Aside from Spanish being one of the top 2 languages for its fans across social media during Inter Miami's inaugural season, more than 60% of website traffic came from Latino dominant cities across the U.S. Also, 34% of Inter Miami's registered mobile app users identified themselves as being of Hispanic/Latino descent. As a part of the multiplatform media campaign, AutoNation will become the sponsor of the "Saves" feature during Inter Miami matches. For every Inter Miami goalkeeper save, AutoNation and Inter Miami will donate up to $100,000 towards cancer research annually.

08:35 EDT Mohawk Group closes previously announced debt refinancing - Mohawk Group Holdings announced that it has closed the refinancing of all of its previously outstanding debt, including two senior secured notes and its revolver credit facility. The Company previously announced its intent to refinance its outstanding debt on March 8, 2021. Pursuant to the refinancing, Mohawk issued senior secured promissory notes in an aggregate principal amount of $110M to two affiliated institutional lenders for a cash payment to Mohawk of $57.7M and the exchange of two senior secured promissory notes with an aggregate principal amount of $52.3M previously issued to the institutional lenders. $14.8M of the net proceeds were used to repay all amounts owed under the Company's Amended and Restated Credit and Security Agreement with MidCap Funding X Trust. The new senior secured promissory notes have an 8% annual interest rate payable in cash on a quarterly basis with a three year maturity. In connection with the refinancing, the Company issued to the institutional lenders warrants to purchase an aggregate of 2,259,166 shares of the Company's common stock with an exercise price of $31.74 per share. The Company expects to use the remaining net proceeds of $40.8M, after deducting fees and expenses, for potential acquisitions, working capital and general corporate purposes.

08:32 EDT ChemoCentryx announces poster presentation on CCX559 - ChemoCentryx announced that the Company's orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research. The poster presentation, which showcases CCX559's ability to induce anti-tumor immunity, will go live on Saturday, April 10 at 8:30 a.m. ET as part of the Novel Antitumor Agents Session. PD-L1/PD-1 interaction is one of the major checkpoints that limit effector T cell function against cancer cells. As a next generation therapy, small molecule inhibitors of PD-L1 may have advantageous properties compared to approved monoclonal antibodies, such as better penetration into solid tumors, reduced immunogenicity, lack of Fc-mediated side effects, convenience of oral administration, and lower cost of goods. The study featured in the AACR poster presentation demonstrated that CCX559 potentially employs distinct mechanisms to inhibit PD-L1 compared to the anti-human PD-L1 antibodies. In murine tumor models, orally administered CCX559 reduced tumor growth similarly to a clinically-approved anti-human PD-L1 antibody. Based on CCX559's unique mechanism of PD-L1 inhibition, strong anti-tumor activity, desirable drug properties, and good safety profile, the Company plans to advance CCX559 into clinical development in the first half of 2021.

08:15 EDT PHX Energy Services increases 2021 capital expenditure program - PHX Energy Services announces that its Board of Directors has approved a $10M increase to the Corporation's 2021 capital expenditure program and anticipates allocating $8M of this increase towards growth capital and $2M towards maintenance. With this increase the Corporation now anticipates spending $25M in capital expenditures during the 2021-year. PHX Energy expects to dedicate the additional capital expenditures to the growth of the Velocity Real Time System and Atlas high performance drilling motor fleets. The company said, "In the first quarter of 2021, the Corporation has experienced an uptick in activity from the last quarter of 2020 as industry activity has continued to rebound. Both Velocity and Atlas continue to be in high demand and the Corporation anticipates further strengthening in both Canada and the US in the later half of the year. With this anticipated level of demand in North America and the recently announced new technology partnership in the Middle East North Africa regions, PHX Energy believes its fleet would reach capacity in the second half of 2021." The increase to its 2021 Program will provide equipment to meet the anticipated demand within its global operations. Additionally, there are sizes of equipment required in the MENA region that differ from those in North America and a portion of the expenditures will be directed towards equipping the MENA fleet with the capabilities to meet these requirements. The 2021 program is expected to be financed from a combination of cash flow from operations and the Corporation's cash on its balance sheet.

08:07 EDT Affimed N.V. announces clinical data from cbNK cells with AFM13 study - Affimed N.V. announced initial clinical data from an investigator-sponsored study at The University of Texas MD Anderson Cancer Center evaluating cord blood-derived natural killer, or cbNK, cells pre-complexed with Affimed's innate cell engager AFM13. The open-label, non-randomized, single-center, dose-escalation trial is evaluating the pre-complexing of AFM13 with cbNK cells followed by three weekly infusions of AFM13 monotherapy in adult patients with recurrent/refractory CD30-positive lymphomas. As of March 31, three patients have been dosed with two cycles of therapy in dose cohort 1 and one patient has received a single cycle of therapy in dose cohort 2. The study is currently enrolling patients in the second dose cohort of NK cells, and further updates are expected later in 2021. Results from the first cycle of the first dose cohort are being presented at AACR, and Affimed is supplementing the data with best responses as of March 31. There were no observed events of cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease. Response evaluation followed the Lymphoma Response to Immunomodulatory Therapy Criteria, or LYRIC. All four patients had relapsed/refractory Hodgkin Lymphoma and were heavily pretreated, with between 4 and 14 previous lines of therapy which in all cases included brentuximab vedotin and anti-PD1 antibodies. Of note, patient #4 had also previously received a CD30-CAR-T.

08:06 EDT Blucora shareholder sends open letter in support of incumbent directors - Jonathan Foster, President and CEO of Angeles Wealth Management and a personal shareholder of Blucora, issued an open letter expressing support for the incumbent Board of Directors at the upcoming 2021 annual meeting of stockholders, scheduled to be held on April 21, 2021. The letter read, "In watching the proxy fight process unfold and reading the dialogue from both sides, I feel compelled to make my opinion known as a fellow personal shareholder. Angeles Wealth Management, and its affiliate Angeles Investment Advisors, do not hold any interest in Blucora. I have been a private client advisor and operator of advisory businesses for over 30 years. I'm currently the President & CEO of Angeles Wealth Management, and former President of Carson Wealth and Howard Capital, as well as the former Head of Wealth Management for ETrade Financial. I have known Todd Mackay, the President of the Advantax Wealth Management division of Blucora, since we worked together at ETrade, and he is the right person to run the advisory business. He has a deep understanding of the RIA/Independent Rep business. Blucora has positioned itself extremely well, and the businesses should stay together. They are a home for tax prep and tax-efficient wealth management. It is 100% branding consistent. On the advisor side, they focus exclusively on offering an advice platform to CPAs who want to expand their services to their clients. CPAs are incredibly tax-sensitive, so the branding/messaging around Advantax as an after-tax focused investment platform is strategically sound and a very smart move. It will attract more CPAs, and they will be able to market the services because they really believe in the after-tax focus. Ancora's comments about Advantax driving advisors away from the direct-to-fund model is misguided. It is absolutely in the best interest of the clients, the advisors and Advantax to move from an independent rep commission model to a true fiduciary advice model. I am voting my proxy with management."

08:04 EDT Mersana Therapeutics announces initiation of Uplift for UpRi in ovarian cancer - Mersana Therapeutics announced the initiation of patient dosing in Uplift, a single-arm registration strategy to evaluate the safety and efficacy of upifitamab rilsodotin in patients with platinum-resistant ovarian cancer who have received up to four lines of therapy. Uplift will evaluate the safety and efficacy of UpRi in patients with platinum-resistant ovarian cancer who have received up to four lines of therapy. There is no exclusion for patients with baseline peripheral neuropathy. Patients may enroll without regard to NaPi2b expression; however, the role of the biomarker will be evaluated. The primary endpoint will be the objective response rate, or ORR, in the high NaPi2b population and the secondary endpoints will be the ORR regardless of NaPi2b expression, as well as duration of response and safety. The single-arm registration strategy is an amendment to the ongoing multinational, multi-center, open label study protocol, and the company expects to enroll approximately 100 patients with high NaPi2b expression and up to 180 patients overall.

08:03 EDT Tenax Therapeutics announces publication of HELP study data - Tenax Therapeutics announced the publication of data from the company's Phase 2 HELP study that evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction, or PH-HFpEF. The new publication is titled Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Placebo-Controlled HELP Trial and was published in the Journal of American College of Cardiology: Heart Failure. The HELP study was designed as a randomized placebo-controlled trial to evaluate the hemodynamic and clinical effects of weekly levosimendan IV infusions in PH-HFpEF patients. This six-week study design evaluated invasive cardiovascular hemodynamics as well as secondary clinical endpoints including a six-minute walk test. Results reported in the publication include an impressive responder rate of 84% during the open-label phase as 37 of 44 patients met responder criteria and were randomized to levosimendan or placebo. Compared with placebo, levosimendan did not significantly reduce the primary endpoint of exercise-PCWP, but effectively reduced PCWP measured across all exercise stages. Levosimendan treatment resulted in a 29.3 meter improvement in 6 MWD compared to placebo. The authors concluded that further study of levosimendan in PH-HFpEF patients is warranted since levosimendan is the first drug to demonstrate improved cardiovascular hemodynamics and a statistically significant increase in six-minute walk distance seen compared to placebo

08:01 EDT Coupa Software announces strategic partnership with Japan Cloud - Coupa Software announced a strategic partnership with Japan Cloud to establish a joint venture known as Coupa K.K. This joint venture will enable Coupa to scale to support the growing number of Japanese companies looking to gain greater efficiency and agility through Business Spend Management. Coupa K.K. will be led by Takashi Ozeki who joins as general manager from Japan Cloud.

07:51 EDT JinkoSolar drops 11% to $34.52 after mixed Q4 results - The company's Q1 revenue guidance trailed estimates.

07:40 EDT Plus Products announces limited-edition release of hash-based gummies - Plus Products announced the launch of its PLUS Hash Gummies in concert with Biscotti Brands which will be available for purchase in California for a limited time. The Company's orange blossom-flavored PLUS Hash Gummies are infused with cold water hash extracted from MAC flower. Each gummy contains 10mg of THC and is flavored with all-natural essence from Seville and Valencia oranges and orange blossom.

07:39 EDT GSX Techedu 'firmly denies' allegations in Grizzly Research report - The company stated, "GSX Techedu firmly denies the false and ungrounded allegations raised in a report by Grizzly Research dated April 8, 2021. The company strongly believes that the report contains numerous errors, unsubstantiated statements, and misinterpretation of information. GSX will consider any necessary and appropriate course of action to protect the interest of the company and all of its shareholders, as well as its students, parents, employees and other stakeholders. The company endeavors to provide full and accurate disclosure to investors and to rebut any false claims that attempt to impair market confidence in GSX's business, operations and financial statements. GSX is committed to maintaining the highest standards of corporate governance, as well as transparent and timely disclosure in compliance with the applicable rules and regulations of the United States Securities and Exchange Commission and the New York Stock Exchange."

07:35 EDT Dundee Precious Metals reports Q1 consolidated ore processed 762.3 Kt - Reports 70.3 K oz. of gold and 7.2 Mlbs of copper in concentrate produced. Dundee Precious Metals announced preliminary production results from both of its mines and smelter for the three months ended March 31, 2021. The Company confirmed that its mining operations are on track to meet previously issued guidance for 2021 and provided updated guidance for its Tsumeb smelter in Namibia. Ada Tepe continued to deliver impressive performance, achieving a new quarterly record for gold production of approximately 33,400 ounces, which was slightly ahead of expectations. Ada Tepe is on track to achieve its previously issued 2021 guidance.Chelopech produced approximately 36,900 ounces of gold and 7.2 million pounds of copper in the first quarter, which was slightly lower than forecast due to lower copper grades as well as lower copper and gold recovery performance with certain ore blends. Chelopech remains on track to achieve 2021 guidance. Complex concentrate smelted was expected to be lower in the first quarter than the remainder of the year, primarily due to the planned Ausmelt furnace shutdown at Tsumeb. During the quarter, Tsumeb processed approximately 23,000 tonnes of complex concentrate, which was slightly below the guidance range of 25,000 to 30,000 tonnes provided in the Company's news release dated March 3, 2021 and below expectations for the quarter. The Ausmelt maintenance, which was originally planned for 30 days, was extended to 45 days and was combined with additional converter maintenance that was also completed during the first quarter. The longer-than-planned timeline was primarily a result of COVID-19 related safety protocols, travel restrictions and the use of remote commissioning support, as well as a decision to increase the scope of the maintenance work around the Ausmelt lining replacement. The Ausmelt maintenance was completed during the first quarter and full operations resumed at the end of March. As a result of the extended shutdown and additional maintenance activities, DPM has revised its 2021 guidance for Tsumeb to 200,000 to 220,000 tonnes of complex concentrate smelted from the previous range of 220,000 to 250,000 tonnes. On March 30, 2021, DPM announced a mine life extension and updated Mineral Resource and Mineral Reserve estimate for the Chelopech mine. Chelopech successfully added 3.9 million tonnes to Mineral Reserves, which more than offset 2020 production depletion of 2.2 Mt for a net addition of 1.7 Mt. Relative to the previous Mineral Reserve estimate, this represents an increase of 10% in tonnage and an increase in metal content of 5% for gold, 13% for silver and 3% for copper. Proven and Probable Mineral Reserves of 1.7 million ounces of gold and 344.4 million pounds of copper support an optimized mine life that extends to 2029 as well as the Company's previously issued three-year outlook for Chelopech. In addition, Measured and Indicated Mineral Resources, exclusive of Mineral Reserves, increased by 22%, representing a 3.2 Mt net increase in tonnage and an increase in metal content of 12% for gold and 6% for copper, which further adds to the potential to extend mine life at Chelopech. DPM continues to focus on extending mine life at Chelopech through its in-mine and brownfield exploration programs, with an extensive program planned for 2021 that includes 44,000 metres of in-mine drilling and 38,000 metres of drilling on prospective brownfield targets.

07:33 EDT Global Internet of People entered into service contracts worth $923,640 - Global Internet of People announced that its subsidiary, Global Mentor Board Information Technology, or GMB, entered into several contracts worth a total of approximately $923,640 in March 2021. On March 29, GMB entered into a service contract with Jiangsu Zhejiang Shanghai Life Sciences Development, or JZS. Pursuant to the service contract, the company will provide JZS with consulting services including business negotiation, strategic planning, financing and investment, in exchange for the equity shares of JZS valued at approximately $685,498. Additionally, GMB entered into several membership service contracts worth a total of approximately $238,145 with enterprise clients. Pursuant to these contracts, GMB will provide these enterprises customized consulting services including business strategy advisory, business development and product marketing to those enterprise clients.

07:08 EDT Telus to invest $2M in Mekinac, des Chanaux RCMs in 2021 - TELUS is investing nearly $2 million in the Mekinac and des Chenaux RCMs in 2021 and will accelerate the deployment of its PureFibre and 5G networks. TELUS' investments in 2021 include the following projects: Deploying the TELUS PureFibre network to more than 1,200 families and businesses in Saint-Prosper, Saint-Stanislas, and Saint-Adelphe. TELUS will continue investing next year to bring high-speed service to even more premises in Mekinac and des Chenaux. Bringing the TELUS 5G network, utilizing current spectrum holdings, to select communities in the region, including in Saint-Tite. Improving wireless coverage by bringing a new telecommunications site to Saint-Adelphe and expanding TELUS' 4G LTE network. TELUS also submitted projects to the CRTC under its Broadband Fund program with the goal of deploying its 4G LTE network in Notre-Dame-de-Montauban and Sainte-Thecle.

07:04 EDT Kraken Robotics enters LOI to acquire PanGeo Subsea - Kraken Robotics announced that it has entered into a non-binding letter of intent dated April 8, 2021 in connection with the proposed acquisition of PanGeo Subsea from Cahill Innovation and Argentum Asset Management. Moya Cahill, a director of Kraken, is a shareholder of Cahill Innovation Inc, and she resigned as a director of Kraken prior to the approval and execution of the LOI in order to ensure proper governance and review of the transaction by a fully arm's length board. The company said, "PanGeo is a private Canadian services company specializing in high resolution 3D acoustic imaging solutions for the sub-seabed. This proposed acquisition would accelerate Kraken's transformation to a Robotics/Data as a Service model by increasing recurring service revenue and providing increased exposure to the non-defense market, including the offshore renewable energy market. Following completion of the proposed acquisition, Kraken would offer a holistic solution of world-leading technologies and services in subsea acoustic and optical imaging: Kraken's suite of ultra-high resolution seabed 3D acoustic imaging sensors, autonomous robotics, and optical laser scanning paired with PanGeo's suite of leading-edge sub-seabed high resolution 3D acoustic imaging systems." Although the LOI remains non-binding, it is anticipated that the purchase price will be between $18-$24M, based on PanGeo's performance over the 2-year period following the acquisition, to be paid by way of cash and stock over that period. Based on initial information provided by the target, the unaudited consolidated assets at December 31, 2020, of the business that Kraken is proposing to acquire were $11.7M and net debt was $0.4M. Unaudited trailing 12-month revenues for the period ended December 31, 2020, were $9M and the corresponding EBITDA was a loss of $0.5N. ThiM was down from comparable 2019 revenues of $10.8M and EBITDA of $2.3M. The year-over-year decline was largely due to the impact of COVID on customer activity. Completion of the acquisition is subject to, among other matters, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, and satisfaction of certain other conditions to be negotiated therein. Given the materiality to Kraken, it is not anticipated that any Kraken shareholder approval would be required to complete the proposed acquisition. Pursuant to the LOI, the parties have agreed to a 60-day exclusivity period during which they will complete their due diligence and negotiate exclusively with each other with a view to settling the terms of the transaction and the form of definitive agreement. Further details will be provided upon successful completion of the due diligence period and the signing of a definitive agreement. The LOI may be terminated by either party if a definitive agreement is not entered into by May 31, 2021. In addition to other conditions, the proposed acquisition remains subject to the approval of the TSX Venture Exchange.

07:03 EDT Five Star Senior Living to amend Diversified Healthcare Trust management deal - Five Star Senior Living (FVE) announced a new strategic plan to reposition its senior living management business to focus on larger independent living, assisted living and memory care communities as well as stand-alone active adult and independent living communities. As part of the implementation of this new plan, Five Star will be amending its management arrangements with Diversified Healthcare Trust (DHC), or DHC, to allow for the transition of 108 smaller senior living communities with approximately 7,500 living units, which Five Star currently manages for DHC, to other operators. Five Star will also close and reposition the skilled nursing units in all continuing care retirement communities, or CCRCs, that Five Star will continue to manage for DHC, which includes approximately 1,500 living units. The transition of management to other operators as well as the closing and repositioning of the skilled nursing units in the CCRCs is expected to be completed before year end 2021. Five Star will continue to operate 144 senior living communities with approximately 20,200 living units, including managing 120 senior living communities with approximately 17,900 living units for DHC, as well as operating its existing owned and leased portfolio of 24 communities with approximately 2,300 living units. Five Star will also continue to grow its rehabilitation and wellness services business. The portfolio Five Star will continue to manage for DHC represents 66% of the existing managed portfolio units and approximately 60% of Five Star's management fee revenues for the year ended December 31, 2020. This retained portfolio of 120 communities managed for DHC outperformed the total DHC managed portfolio with 110 basis points higher average occupancy and 280 bps higher EBITDA margin for the year ended December 31, 2020. The communities to be transitioned represent approximately 40% of Five Star's management fee revenues from DHC, but less than 12% of Five Star's total management and operating revenues for the year ended December 31, 2020. Five Star expects to partially offset the resulting revenue loss with expense reductions to right-size operations. Five Star expects to incur net non-recurring restructuring costs of up to $5.5M in connection with implementing this new strategic plan. In connection with this new strategic plan, Five Star and DHC have also agreed to make certain additional changes to their management arrangements, including extending the term to December 31, 2036, eliminating DHC's right to sell communities without payment to Five Star of a termination fee, eliminating the cap on Five Star's incentive fee and modifying DHC's rights to terminate for performance.

07:01 EDT RedHill Biopharma's Phase 2/3 COVID-19 study of opaganib passes DSMB review - RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib in patients hospitalized with severe COVID-19 pneumonia has received a unanimous recommendation to continue, following a fourth independent Data Safety Monitoring Board safety review. The DSMB's recommendation is based on an analysis of unblinded safety data from the first 255 patients treated for 14 days, extending the total opaganib safety database to approximately 380 patients.

06:54 EDT Sanofi says interim late-breaking data validate not-alpha profile of THOR-707 - Interim data from a first-in-human trial evaluating the safety, therapeutic activity and maximum tolerable dose of THOR-707, a highly differentiated not-alpha interleukin-2 candidate, as a monotherapy and in combination with anti-PD-1, will be presented Saturday, April 10 as a late-breaking poster presentation at the American Association for Cancer Research, or AACR, Annual Meeting, Sanofi announced. The Saturday late-breaking poster session will include additional updated data. Interim safety, anti-tumor activity and biomarker data further validate the not-alpha IL-2 profile seen preclinically. In both the combination and monotherapy settings, initial activity was observed, with three confirmed partial responses, which includes patients who have received prior anti-PD-1 therapeutics, the company said. "THOR-707 has a potentially best-in-class profile and reinforces the promise of our Synthorin technology platform to overcome difficult targets with precision biology. The activity observed both as single agent and with an anti-PD-1 further strengthens our belief that as a unique not-alpha IL-2, THOR-707 could become a backbone of future immuno-oncology therapies. We will continue to explore the molecule's potential for best-in-disease combinations," said John Reed, M.D. Ph.D., Global Head of Research & Development, Sanofi.

06:10 EDT The9 signs MOU to purchase 2,000 Bitcoin mining machines in exchange for shares - The9 announced that it signed a legally binding memorandum of understanding, or MOU, with an unrelated Bitcoin mining machine owner to purchase Bitcoin mining machines by the issuance of Class A ordinary shares. This batch of Bitcoin mining machines consists of 2,000 units of AvalonMiners with total hash rate of approximately 100PH/S. According to the MOUs, The9 will issue approximately 8,127,390 Class A ordinary shares to the sellers based on The9 share price of US$24.81 prior to the MOU, with a lock up period of six months. The number of Class A ordinary shares to be issued is subject to certain price adjustment mechanisms to be assessed six months after the signing of the definitive agreements. The9 will designate an independent valuation firm to conduct examination and assessment of the Bitcoin mining machine fair market value, and will make adjustment to the number of Class A ordinary shares to be issued if needed. The9 also announced that it completed the signing of the definitive agreements for 12,246 units of Bitcoin mining machines with total hash rate of approximately 288PH/S. The number of Class A ordinary shares to be issued is calculated with reference to the fair market values on the valuation reports issued by an independent valuation firm and The9 share price prior to the respective memorandums of understanding signing date. The9 will issue a total number of 9,387,840 Class A ordinary shares to the sellers, with a lock up period of six months.

06:05 EDT Ebang to respond to Hindenburg allegations in open letter to shareholders - Ebang announced that it plans to address the shareholders in an open letter at the beginning of next week to respond to allegations in the short seller report issued by Hindenburg Research on April 6. In the open letter, the management will reaffirm its vision for the company's future and provide updates to its ongoing expansion plans. Such letter is further expected to reaffirm the company's commitment to create value for all shareholders and take whatever necessary and appropriate actions that may be required to protect the interest of its shareholders.

06:01 EDT Amdocs selected by Fastweb to modernize mission-critical inventory systems - Amdocs announced that it has been selected by Fastweb, a Italian telecommunications operator, to modernize its mission-critical inventory systems, as part of its ongoing initiative to transform its IT systems into a flexible and 5G-ready platform to grow and differentiate its business. As part of the deal, Amdocs will upgrade Fastweb's Network Inventory to the next-generation OSS solution, providing inventory, network navigation, reporting and ongoing maintenance, supporting the transformation of Fastweb's IT into an open and dynamic infrastructure, enhancing the overall experience for Fastweb's customers.

05:15 EDT Toshiba chairperson Osamu Nagayama comments on CVC Capital acquisition proposal - Osamu Nagayama, chairperson of the board of directors of Toshiba has commented on the acquisition proposal from CVC Capital Partners as follows: "As announced in the public statement dated April 7th, Toshiba has received a preliminary and non-legally binding initial proposal from CVC Capital Partners (CVC) regarding the acquisition of Toshiba and to get the same privatized. This initial proposal by CVC was completely unsolicited and not initiated by Toshiba by all means. The proposal does not go through detailed review of Toshiba business. Further, CVC's initial proposal is conditional on a variety of matters such as clearances of the Anti-trust registrations of the relevant jurisdictions, the Foreign Exchange and Foreign Trade Act of Japan and necessary financing. Furthermore, the proposed transaction is not contemplated to be financed by CVC alone; rather, it is indicated in CVC's proposal that it would seek financing assistance from certain co-investors and financial institutions in pursuing the proposed transaction. We expect that such financing process would require a substantial amount of time and involve complexity for consideration. It is the Board's responsibility to act for the benefit of the best interests of the Company and our shareholders. Toshiba Board will conduct careful review of the initial proposal when it is further clarified in the future."